Abstract: Provided is a preparation of ramosetron which is stable under irradiation with light. The solid pharmaceutical composition of the present invention can provide a stable preparation by blending a compound absorbing light having a specific wavelength with ramosetron which is unstable, usually under irradiation with light, or a pharmaceutically acceptable salt thereof. Particularly, this technique is useful because it is adaptable to a preparation containing ramosetron or a pharmaceutically acceptable salt thereof at a low content or an orally disintegrating tablet containing ramosetron or a pharmaceutically acceptable salt thereof. Also, the present invention relates to a method for stabilizing a solid pharmaceutical composition of ramosetron or a pharmaceutically acceptable salt thereof, which is characterized by blending a compound having characteristics of absorbing light having a specific wavelength.

Abstract: A pharmaceutical composition comprising aminoalkyl methacrylate copolymer E, an acidic substance, and a poorly-soluble drug, wherein the aminoalkyl methacrylate copolymer E and the acidic substance are uniformly mixed, and solubility of the poorly-soluble drug is maintained for at least 30 minutes is disclosed.

Abstract: The present invention relates to the provision of a stable particulate pharmaceutical composition of solifenacin or a salt thereof, which is in a spherical shape suitable for coating and in which degradation with time can be inhibited when a pharmaceutical preparation of solifenacin or a salt thereof is supplied to clinical fields. More particularly, it relates to a particulate pharmaceutical composition that can be obtained by using a binder having a Tg or mp lower than 174C upon formulating a particulate composition of solifenacin into a pharmaceutical preparation. Further, by performing a crystallization-promoting treatment after the particulate pharmaceutical composition is produced, a more stable particulate composition of solifenacin or a salt thereof can be provided.